AlphAIalphai — Financial news for AI agents
Stock TitanMAR 202 min read$HAO

Liu Jia at Haoxi Health (NASDAQ: HAO) files initial Form 3 report

Haoxi Health Technology Ltd director Liu Jia has submitted an initial insider ownership report on Form 3. The filing indicates Liu Jia is a director of the company but shows no reported transactions, share purchases, sales, or derivative positions for the reporting person. The document also provides details on the SEC Form 3 and clarifies that no securities are beneficially owned according to this initial report.

Original reporting
Stock Titan
Published Mar 20, 2026, 6:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 20, 2026, 6:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Liu Jia at Haoxi Health (NASDAQ: HAO) files initial Form 3 report — source image
Source · Stock Titan
Decision brief

The 30-second read

$HAONeutralLow
01

Why it matters

The filing indicates no changes in insider ownership or transactions, suggesting stability in insider holdings.

02

Market read

This news has limited immediate trading relevance, primarily confirming existing insider ownership status.

03

What to watch

Potential undisclosed transactions or future filings could alter the outlook; monitoring for updates is advisable.

Timing: low

Background

Liu Jia, a director of Haoxi Health Technology Ltd (NASDAQ: HAO), filed an initial Form 3 report, which is a standard insider ownership disclosure.

Company-level read

Ticker impact

$HAONeutralHigh confidence
Context

The news pertains to insider reporting for Haoxi Health Technology Ltd, which is relevant for assessing insider ownership and potential market impact.

Expected impact

Minimal to no immediate price movement expected due to lack of new ownership information.

Evidence & confidence

The report shows no transactions or ownership changes, indicating stability in insider ownership and limited impact on stock price.

Market effects

Sector

Limited sector impact as the news is specific to insider reporting without broader market or sector changes.

Regional

Negligible impact on regional markets.

Global

Minimal relevance to global markets.

Counterpoint

What could challenge this read

Some traders might interpret the lack of insider activity as a sign of potential upcoming developments, but current evidence does not support this.

Key entities

  • Person
    Liu Jia

    Director of Haoxi Health Technology Ltd.

  • Company
    Haoxi Health Technology Ltd

    A healthcare technology company listed on NASDAQ.

Read at source← All news

Related articles

AUG 25
$FISHigh

Wells Fargo Cuts FIS Stock Target to $46. Still No Analyst Calls It a Sell, Here’s Why.

Wells Fargo cut its price target for Fidelity National Information Services (FIS) to $46 from $58, citing concerns over the Capital Markets segment. Despite this, no analysts rate FIS a sell, and the stock trades at a 23% discount to the mean target. FIS raised its free cash flow guidance for 2026 to $2.15B-$2.25B, up 36% at the midpoint. The stock closed at $41.40 on August 24, 2026.

tikr.com2 min
AUG 25
$PLTRHighAI 8/10

Palantir's Maven Is Now an Official Pentagon Program of Record. Here's What Guaranteed Budget Dollars Are Worth.

Palantir Technologies (PLTR) announced that its Maven Smart System, an AI-powered military platform, has been designated an official Pentagon program of record. This designation could secure $2.3 billion in funding over five years. Maven analyzes battlefield data and supports AI-enabled targeting, making it a key tool for the U.S. military. Palantir's government contracts, including Maven, contributed significantly to its revenue, with $809 million from U.S. government contracts in Q2, up 90% ye

yahoo.com2 min
AUG 25
$HRLLow

Hormel names ex-Tyson executive as new CFO

Hormel Foods appointed Ash Bhumbla, a former Tyson Foods executive, as its new CFO, effective September. Bhumbla succeeds Paul Kuehneman, who will remain a senior leader. Hormel reported strong Q2 results and is set to release Q3 earnings on Thursday, according to the company.

thepoultrysite.com1 min